Kaleido Bioscience

Missed target failed trial trial failure

Biotech

Another Flagship biotech focused on the microbiome struggles

Evelo is moving on from its lead asset after additional dose cohort data in patients with atopic dermatitis mirrored past failures.

Max Bayer Apr 26, 2023 10:45am

new dimension abstract door

A new dimension: Biotech VC unveils with $350M

Jan 25, 2023 11:31am

topic report

Graphic image of a graveyard with tombstones a full moon and a raven perched on a branch

The 2022 Biotech Graveyard

Nov 21, 2022 3:00am